By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German chemical proteomics firm Kinaxo Biotechnologies today announced a collaboration with AstraZeneca in support of one of its oncology programs.

Under the terms of the deal, Kinaxo will use it mass spectrometry-based technologies to quantitatively analyze post-translational modifications in proteins on a proteome-wide scale, it said in a statement. Information from the analyses is anticipated to provide insight into the cellular functions of potential drug targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.